TABLE 2.
Distribution of resistance phenotypes among different serogroups
| Resistance phenotypea | No. (%) of isolates in serogroup
|
No. of MR isolatesb | Total no. (%) of isolates (n = 88) | ||||
|---|---|---|---|---|---|---|---|
| O:12 (n = 22) | O:11 (n = 14) | O:1 (n = 15) | O:6 (n = 9) | Other (n = 28) | |||
| T | 1 | 3 | 1 | 5 | 8 (11) | ||
| A | 1 | 2 | 1 | 1 | 5 (6) | ||
| M | 1 | 1 | 2 | ||||
| I | 2 | 2 | |||||
| AP | 1 | 1 | 1 | ||||
| TA | 1 | 1 | 5 | 7 (8) | |||
| TG | 1 | 1 | 1 | ||||
| GN | 1 | 1 | |||||
| MN | 1 | 1 | |||||
| TAG | 1 | 1 | 2 | 2 | |||
| TCA | 1 | 1 | |||||
| TGB | 1 | 1 | 1 | ||||
| GMN | 1 | 1 | |||||
| TCAN | 1 | 1 | 1 | ||||
| AGMN | 1 | 1 | 1 | ||||
| TAMP | 1 | 1 | 1 | ||||
| TIPR | 1 | 1 | 1 | ||||
| TAIPR | 1 | 1 | 1 | ||||
| TCAGMN | 1 | 1 | 1 | ||||
| TAGBMN | 1 | 1 | 1 | ||||
| TCAGBMN | 2 | 2 | 2 | ||||
| TCAGMPR | 1 | 1 | 1 | ||||
| TAGBMNP | 1 | 1 | 1 | ||||
| TAGBNPR | 1 | 1 | 1 | ||||
| TAIGBNP | 1 | 1 | 1 | ||||
| TCAIGMNP | 1 | 1 | 1 | ||||
| TAGBMNPR | 4 | 1 | 5 | 5 (6) | |||
| TAIGBNPR | 1 | 1 | 2 | 2 | |||
| TCAGBMNPR | 2 | 1 | 3 | 3 | |||
| TAIGBMNPR | 6 (27) | 1 | 7 | 7 (8) | |||
| TCAIGBMNPR | 6 (27) | 2 | 1 | 9 | 9 (10) | ||
| Fully susceptible | 1 (7) | 1 (7) | 3 (33) | 8 (29) | 13 (15) | ||
| Total MRb | 20 (91) | 11 (79) | 6 (40) | 3 (43) | 6 (25) | 46 (52) | |
| % of total MRb | 43 | 24 | 13 | 7 | 13 | ||
a
T, ticarcillin; C, ceftazidime; A, aztreonam; I, imipenem; G, gentamicin; B, tobramycin; M, amikacin; N, netilmicin; P, ciprofloxacin; R, norfloxacin.
b
MR, multidrug resistant (resistant to two or more antibiotic classes). High and intermediate levels of resistance have been grouped together.